As an additional treatment option, the inclusion of olaparib maintenance therapy demonstrated a significant advantage in terms of progression-free survival for women who were diagnosed with newly advanced ovarian cancer and carried a BRCA1/2 mutation (6). The gene discussed is BRCA1; the disease is ovarian carcinoma.